Obinutuzumab: first global approval (Q34391958)

1 August 2017

title

Obinutuzumab: first global approval (English)

1 reference

1 August 2017

Fiona Cameron

1

1 reference

1 August 2017

Paul L McCormack

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2014

1 reference

1 August 2017

1 reference

1 August 2017

volume

74

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

147-154

1 reference

Advances in the management of follicular lymphoma

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Current status of targeted therapies for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Novel agents in indolent lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-013-0167-3

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24338113

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0167-3

1 reference

Dimensions Publication ID

1 August 2017

1007316120

0 references

1 reference